TY - JOUR
T1 - A preclinical xenograft model of prostate cancer using human tumors
AU - Lawrence, Mitchell Graham
AU - Taylor, Renea Anne
AU - Toivanen, Roxanne
AU - Pedersen, John S
AU - Norden, Sam
AU - Pook, David William
AU - Frydenberg, Mark
AU - Australian Prostate Cancer BioResource
AU - Papargiris, Melissa
AU - Niranjan, Birunthi
AU - Richards, Michelle Giustina
AU - Wang, Hong
AU - Collins, Anne T
AU - Maitland, Norman J
AU - Risbridger, Gail Petuna
PY - 2013
Y1 - 2013
N2 - Most cases of prostate cancer are now diagnosed as moderate-grade localized disease. These tumor specimens are important tools in the discovery and translation of prostate cancer research; however, unlike more advanced tumors, they are notoriously difficult to grow in the laboratory. We developed a system for efficiently xenografting localized human prostate cancer tissue, and we adapted this protocol to study the interactions between the specific subsets of epithelial and stromal cells. Fresh prostate tissues or isolated epithelial cells are recombined with mouse seminal vesicle mesenchyme (SVM) and grafted under the renal capsule of immunodeficient mice for optimum growth and survival. Alternatively, mouse mesenchyme can be replaced with human prostate fibroblasts in order to determine their contribution to tumor progression. Grafts can be grown for several months to determine the effectiveness of novel therapeutic compounds when administered to host mice, thereby paving the way for personalizing the treatment of individual prostate cancers.
AB - Most cases of prostate cancer are now diagnosed as moderate-grade localized disease. These tumor specimens are important tools in the discovery and translation of prostate cancer research; however, unlike more advanced tumors, they are notoriously difficult to grow in the laboratory. We developed a system for efficiently xenografting localized human prostate cancer tissue, and we adapted this protocol to study the interactions between the specific subsets of epithelial and stromal cells. Fresh prostate tissues or isolated epithelial cells are recombined with mouse seminal vesicle mesenchyme (SVM) and grafted under the renal capsule of immunodeficient mice for optimum growth and survival. Alternatively, mouse mesenchyme can be replaced with human prostate fibroblasts in order to determine their contribution to tumor progression. Grafts can be grown for several months to determine the effectiveness of novel therapeutic compounds when administered to host mice, thereby paving the way for personalizing the treatment of individual prostate cancers.
UR - http://www.nature.com/nprot/journal/v8/n5/pdf/nprot.2013.043.pdf
U2 - 10.1038/nprot.2013.043
DO - 10.1038/nprot.2013.043
M3 - Article
SN - 1754-2189
VL - 8
SP - 836
EP - 848
JO - Nature Protocols
JF - Nature Protocols
IS - 5
ER -
